Clinical Trials

Trial Name Description
PET-BOOST Dr. David Palma
A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy.
A Randomized Phase III Trial of Palliative Radiation of Advanced Central Lung Tumors with Intentional Avoidance of the Esophagus
Checkmate 577 Dr. Mark Vincent
A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer.
Identification of acute radiation-induced cardiac toxicity after non-small cell lung cancer radiotherapy with advanced multi-modality imaging
BR.31 Lung Dr. Sara Kuruvilla
A Phase III Retrospective, Double-Blind, Placebo-Controlled, Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
RELAY - JVCY Lung Dr. M. Vincent
A Multicentre, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
LUSTRE Lung Dr. Alex Louie
A Randomized Trial of Medically-Inoperable Stage I Non-Small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy
IND.227 Dr. Mark Vincent
A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma.
A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy plus Surgery in Early Non-Small Cell Lung Cancer
STOP-NSCLC Dr. David Palma
Sterotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer
NRG-LU002 Dr. Alex Louie
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial.
SUNSET Dr. David Palma
SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial.
B-FAST NSCLC Dr. M. Vincent
A phase II/III multicenter study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring actionable somatic mutations detected in b

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada